المؤلفون: Guangyu Sun, Zhengxin Liang, Yuchen Jiang, Shenfei Ma, Shuaiqi Chen, Ranlu Liu

المصدر: Current Oncology, Vol 29, Iss 11, Pp 8668-8676 (2022)

مصطلحات موضوعية: prostate cancer, neoadjuvant hormone therapy, laparoscopic radical prostatectomy, robot-assisted radical prostatectomy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.mdpi.com/1718-7729/29/11/683; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

URL الوصول: https://doaj.org/article/3df2b9a89ab24c2cbecef383c3fb29f1

المؤلفون: Maria Carolina Gouveia, Candice Amorim de Araújo Lima Santos, Ariani Impieri Souza

المصدر: Contemporary Clinical Trials Communications, Vol 30, Iss , Pp 101013- (2022)

مصطلحات موضوعية: Neoadjuvant chemotherapy, Neoadjuvant hormone therapy, Chemotherapy, Radiotherapy, Presurgical treatment, Preoperative endocrine prognostic index, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2451865422001302; https://doaj.org/toc/2451-8654

URL الوصول: https://doaj.org/article/d83bb68627994f19ac980535b569f8bb

المؤلفون: Wen Liu, Yu Yao, Xue Liu, Yong Liu, Gui-Ming Zhang

المصدر: Asian Journal of Andrology, Vol 23, Iss 4, Pp 429-436 (2021)

مصطلحات موضوعية: high-risk diseases, meta-analysis, neoadjuvant hormone therapy, prostate cancer, prostatectomy, radiotherapy, Diseases of the genitourinary system. Urology, RC870-923

وصف الملف: electronic resource

Relation: http://www.ajandrology.com/article.asp?issn=1008-682X;year=2021;volume=23;issue=4;spage=429;epage=436;aulast=Liu; https://doaj.org/toc/1008-682X; https://doaj.org/toc/1745-7262

URL الوصول: https://doaj.org/article/84d5f3cffa2c4e13b9bde495f8a2e06e

المؤلفون: V. V. Vorotnikov, R. A. Pakhomova, A. V. Soinov, A. S. Gunina, I. V. Kopytich, M. G. Tsoi, S. A. Abdugafforov, В. В. Воротников, Р. А. Пахомова, А. В. Сойнов, А. С. Гунина, И. В. Копытич, М. Г. Цой, С. А. Абдугаффоров

المصدر: Creative surgery and oncology; Том 12, № 3 (2022); 199-204 ; Креативная хирургия и онкология; Том 12, № 3 (2022); 199-204 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: палбоциклиб, neoadjuvant chemotherapy, neoadjuvant hormone therapy, triple negative breast neoplasm, gene expression profiling, tamoxifen, letrozole, taselisib, palbocyclib, неоадъювантная химиотерапия, неоадъювантная гормонотерапия, тройное негативное новообразование молочной железы, профилирование генной экспрессии, тамоксифен, летрозол, таселисиб

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/714/506; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. DOI:10.3322/caac.21660; Australian Institute of Health and Welfare 2019. Cancer in Australia 2019. Cancer series no.119. Cat. no. CAN 123. Canberra: AIHW; 2019.; Puglisi F., Follador A., Minisini A.M., Cardellino G.G., Russo S., Andreetta C., et al. Baseline staging tests after a new diagnosis of breast cancer: Further evidence of their limited indications. Ann. Oncol. 2005;16:263–6. DOI:10.1093/annonc/mdi063; Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008;26:1275–81. DOI:10.1200/JCO.2007.14.4147; Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384:164–72. DOI:10.1016/S0140-6736(13)62422-8; Gianni L., Pienkowski T., Im Y.-H., Roman L., Tseng L.-M., Liu M.-C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32. DOI:10.1016/S1470-2045(11)70336-9; Korde L.A., Somerfield M.R., Carey L.A., Crews J.R., Denduluri N., Hwang E.S., et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485–505. DOI:10.1200/JCO.20.03399; van Ramshorst M.S., van der Voort A., van Werkhoven E.D., Mandjes I.A., Kemper I., Dezentjé V.O., et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–40. DOI:10.1016/S1470-2045(18)30570-9; Zhang D., Lu W., Zhuo Z., Mei H., Wu X., Cui Y. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration. Discov Oncol. 2022;13(1):78. DOI:10.1007/s12672-022-00506-0; Fujii T., Kogawa T., Dong W., Sahin A.A., Moulder S., Litton J.K., et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017;28(10):2420–8. DOI:10.1093/annonc/mdx397; Schneeweiss A., Chia S., Hickish T., Harvey V., Eniu A., Hegg R., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) Ann. Oncol. 2013;24:2278–84. DOI:10.1093/annonc/mdt182; Sikov W.M., Berry D.A., Perou C.M., Singh B., Cirrincione C.T., Tolaney S.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) J. Clin. Oncol. 2015;33:13–21. DOI:10.1200/jco.2014.57.0572; Ellis M.J., Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105(Suppl 1):33–43. DOI:10.1007/s10549-007-9701-x; Smith I.E., Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Blohmer J.U., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16. DOI:10.1200/JCO.2005.04.005; Cataliotti L., Buzdar A.U., Noguchi S., Bines J., Takatsuka Y., Petrakova K., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103. DOI:10.1002/cncr.21872; Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9. DOI:10.1200/JCO.2010.31.6950; Spring L.M., Gupta A., Reynolds K.L., Gadd M.A., Ellisen L.W., Isakoff S.J., et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–86. DOI:10.1001/jamaoncol.2016.1897; Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Ziltsova E.K., Ivanov V.G., Bozhok A.A., et al. Phase 2 randomized trial of primary endocrine therapy vs chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244–54. DOI:10.1002/cncr.22789; Alba E., Calvo L., Albanell J., De La Haba J.R., Lanza A.A., Chacon J.I., et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann. Oncol. 2012;23:3069–74. DOI:10.1093/annonc/mds132; Murray N., Francis P., Zdenkowski N., Wilcken N., Boyle F., Gebski V., et al. Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial. Ann Oncol. 2022;33(3):164–5. DOI:10.1016/j.annonc.2022.03.107; Krainick-Strobel U.E., Lichtenegger W., Wallwiener D., Tulusan A.H., Janicke F., Bastert G., et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;8:62. DOI:10.1186/1471-2407-8-62; Llombart-Cussac A., Guerrero A., Galan A., Caranana V., Buch E., Rodriguez-Lescure A., et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol. 2012;14(2):125–31. DOI:10.1007/s12094-012-0771-9; Carpenter R., Doughty J.C., Cordiner C., Moss N., Gandhi A., Wilson C., et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 2014;144(3):569–76. DOI:10.1007/s10549-014-2835-8; Prat A., Saura C., Pascual T., Hernando C., Munoz M., Pare L., et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33–43. DOI:10.1016/S1470-2045(19)30786-7; Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2016;24(9):2206–23. DOI:10.1093/annonc/mdt303; Harbeck N., Thomssen C., Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel). 2013;8(2):102–9. DOI:10.1159/000351193; Burstein H.J., Curigliano G., Loibl S., Dubsky P., Gnant M., Poortmans P., et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–57. DOI:10.1093/annonc/mdz235; Burstein H.J., Curigliano G., Thürlimann B., Weber W.P., Poortmans P., Regan M.M., et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–35. DOI:10.1016/j.annonc.2021.06.023; Lin M., Jin Y., Zhang J. Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021. Transl Breast Cancer Res 2021;2:17. DOI:10.21037/tbcr-21-7; Jackisch C. Overcoming endocrine resistance in neoadjuvant endocrine therapy for early breast cancer. Lancet Oncol. 2019;20(9):1185–7. DOI:10.1016/S1470-2045(19)30500-5; Saura C., Hlauschek D., Oliveira M., Zardavas D., Jallitsch-Halper A., de la Pena L., et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019;20(9):1226–38. DOI:10.1016/S1470-2045(19)30334-1; Johnston S., Puhalla S., Wheatley D., Ring A., Barry P., Holcombe C., et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol. 2019;37(3):178–89. DOI:10.1200/JCO.18.01624; Cottu P., D'Hondt V., Dureau S., Lerebours F., Desmoulins I., Heudel P.E., et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018;29(12):2334–40. DOI:10.1093/annonc/mdy448; Sestak I., Buus R., Cuzick J., Dubsky P., Kronenwett R., Denkert C., et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):545–53. DOI:10.1001/jamaoncol.2017.5524; Jaber M.I., Song B., Taylor C., Vaske C.J., Benz S.C., Rabizadeh S., et al. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival. Breast Cancer Res. 2020;22(1):12. DOI:10.1186/s13058-020-1248-3; Andre F., Ismaila N., Allison K.H., Barlow W.E., Collyar D.E., Damodaran S., et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO Guideline Update. J Clin Oncol. 2022;40(16):1816–37. DOI:10.1200/JCO.22.00069; Wu H.J., Chu P.Y. Recent discoveries of macromolecule- and cell-based biomarkers and therapeutic implications in breast cancer. Int J Mol Sci. 2021;22(2):636. DOI:10.3390/ijms22020636; Goto-Yamaguchi L., Yamamoto-Ibusuki M., Yamamoto Y., Fujiki Y., Tomiguchi M., Sueta A., et al. Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling. Breast Cancer Res Treat. 2018;172(2):353–62. DOI:10.1007/s10549-018-4933-5; Gao J.J., Swain S.M. Luminal a breast cancer and molecular assays: a review. Oncologist. 2018;23(5):556–65. DOI:10.1634/theoncologist.2017-0535; Cardoso F., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rubio I.T., et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(10):1674. DOI:10.1093/annonc/mdz173; Selli C., Turnbull A.K., Pearce D.A., Li A., Fernando A., Wills J., et al. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours. Breast Cancer Res. 2019;21(1):2. DOI:10.1186/s13058-018-1089-5; Inda M.A., Blok E.J., Kuppen P.J.K., Charehbili A., den Biezen-Timmermans E.C., van Brussel A., et al. Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer. Mol Cancer Ther. 2019;19(2):680–89. DOI:10.1158/1535-7163.MCT-19-0318; Ueno T., Saji S., Masuda N., Iwata H., Kuroi K., Sato N., et al. Changes in recurrence score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. ESMO Open. 2019;4(1):e000476. DOI:10.1136/esmoopen-2018-000476; Vendrell J.A., Solassol J., Gyorffy B., Vilquin P., Jarlier M., Donini C.F., et al. Evaluating ZNF217 mRNA expression levels as a predictor of response to endocrine therapy in ER+ breast cancer. Front Pharmacol. 2018;9:1581. DOI:10.3389/fphar.2018.01581; Bear H.D., Wan W., Robidoux A., Rubin P., Limentani S., White R.L. Jr, et al. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial. J Surg Oncol. 2017;115(8):917–23. DOI:10.1002/jso.24610; Sparano J.A., Gray R.J., Makower D.F., Pritchard K.I., Albain K.S., Hayes D.F., et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. DOI:10.1056/NEJMoa1804710; Russnes H.G., Lingjaerde O.C., Borresen-Dale A.L., Caldas C. Breast cancer molecular stratification: from intrinsic subtypes to integrative clusters. Am J Pathol. 2017;187(10):2152–62. DOI:10.1016/j.ajpath.2017.04.022; Giridhar K.V., Liu M.C. Available and emerging molecular markers in the clinical management of breast cancer. Expert Rev Mol Diagn. 2019;19(10):919–28. DOI:10.1080/14737159.2019.1664901; Gyorffy B., Hatzis C., Sanft T., Hofstatter E., Aktas B., Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2017;17:11. DOI:10.1186/s13058-015-0514-2; Iwata H., Masuda N., Yamamoto Y., Fujisawa T., Toyama T., Kashiwaba M., et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2019;173(1):123–33. DOI:10.1007/s10549-018-4964-y; https://www.surgonco.ru/jour/article/view/714

الاتاحة: https://www.surgonco.ru/jour/article/view/714
https://doi.org/10.24060/2076-3093-2022-12-3-199-204

المؤلفون: Ma BL, Yao L, Fan Y, Wang Y, Meng YS, Zhang Q, He ZS, Jin J, Zhou LQ

المصدر: Cancer Management and Research, Vol Volume 11, Pp 4143-4151 (2019)

مصطلحات موضوعية: localized high-risk, limited advanced, prostate cancer, neoadjuvant hormone therapy, short-term benefit, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/short-term-benefit-of-neoadjuvant-hormone-therapy-in-patients-with-loc-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322

URL الوصول: https://doaj.org/article/51d5935bc89247f9b4929b805ac8c060

المؤلفون: Lijin Zhang, Hu Zhao, Bin Wu, Zhenlei Zha, Jun Yuan, Yejun Feng

المصدر: Frontiers in Oncology, Vol 10 (2021)

مصطلحات موضوعية: prostate cancer, radical prostatectomy, neoadjuvant hormone therapy, meta-analysis, clinical research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2020.615801/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/16154ff6c76f4a859eb4b8f5bf0db896

المؤلفون: Demidov, C. M., Demidov, D. A., Shchigolev, M. I., Демидов, С. М., Демидов, Д. А., Щиголев, М. И., Елишев, В. Г.

مصطلحات موضوعية: BREAST CANCER, NEOADJUVANT HORMONE THERAPY, PRIMARY ENDOCRINE THERAPY, ELDERLY PATIENTS, RELAPSE-FREE SURVIVAL, OVERALL SURVIVAL, BISPHOSPHANATES, РАК МОЛОЧНОЙ ЖЕЛЕЗЫ, НЕОАДЪЮВАНТНАЯ ГОРМОНОТЕРАПИЯ, ПЕРВИЧНАЯ ЭНДОКРИНОТЕРАПИЯ, ПОЖИЛЫЕ ПАЦИЕНТКИ, БЕЗРЕЦИДИВНАЯ ВЫЖИВАЕМОСТЬ, ОБЩАЯ ВЫЖИВАЕМОСТЬ, БИСФОСФОНАТЫ

وصف الملف: application/pdf

Relation: Уральский медицинский журнал. 2020. № 2(185).; Первичная эндокринотерапия рака молочной железы у пациенток старших возрастных групп: обзор литературы / С. М. Демидов, Д. А. Демидов, М. И. Щиголев, В. Г. Елишев. – Текст: электронный // Уральский медицинский журнал. - 2020. – № 2(185). – С. 44-50.; http://elib.usma.ru/handle/usma/18893

الاتاحة: http://elib.usma.ru/handle/usma/18893

المؤلفون: Di Benedetto A., Ercolani C., Pizzuti L., Angelucci D., Sergi D., Marinelli C., Iezzi L., Sperati F., Terrenato I., Mazzotta M., Mariani L., Vizza E., Paoletti G., Tomao S., Maugeri-Sacca M., Barba M., Tinari N., Natoli C., Ciliberto G., Grassadonia A., Vici P.

المساهمون: Di Benedetto, A., Ercolani, C., Pizzuti, L., Angelucci, D., Sergi, D., Marinelli, C., Iezzi, L., Sperati, F., Terrenato, I., Mazzotta, M., Mariani, L., Vizza, E., Paoletti, G., Tomao, S., Maugeri-Sacca, M., Barba, M., Tinari, N., Natoli, C., Ciliberto, G., Grassadonia, A., Vici, P.

مصطلحات موضوعية: DNA damage and repair, elderly patient, hormone-receptor-positive breast cancer, neoadjuvant hormone therapy, prognostic biomarkers

Relation: info:eu-repo/semantics/altIdentifier/pmid/31452691; info:eu-repo/semantics/altIdentifier/wos/WOS:000481815000001; volume:11; firstpage:1758835919853192; journal:THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY; http://hdl.handle.net/11564/711375; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85071722102; http://tam.sagepub.com/content/by/year

الاتاحة: http://hdl.handle.net/11564/711375
https://doi.org/10.1177/1758835919853192
http://tam.sagepub.com/content/by/year

المؤلفون: E. Kipriyanov A., P. Karnaukh A., I. Vazhenin A., T. Sharabura M., A. Vazhenin V., K. Ivakhno Yu., Е. Киприянов А., П. Карнаух А., И. Важенин А., Т. Шарабура М., А. Важенин В., К. Ивахно Ю.

المصدر: Cancer Urology; Том 13, № 2 (2017); 74-78 ; Онкоурология; Том 13, № 2 (2017); 74-78 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-2

مصطلحات موضوعية: prostate cancer, neoadjuvant hormone therapy, brachytherapy 125I, conformal radiotherapy, robotic radiotherapy, рак предстательной железы, неоадьювантная гормонотерапия, лучевое лечение, брахитерапия I-125, конформная лучевая терапия, роботизированная радиотерапия

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/649/661; Зырянов А.В., Баженов А.А., Машковцев А.В. Брахитерапия в лечении больных локализованным раком предстательной железы с доброкачественной гиперплазией предстательной железы. Уральский медицинский журнал 2009;11(65):35–6. [Zyryanov A.V., Bazhenov A.A., Mashkovtsev A.V. Brachytherapy in treatment of patients with localized prostate cancer and benign prostatic hyperplasia. Ural’skiy meditsinskiy zhurnal = Ural Medical Journal 2009;11(65):35–6. (In Russ.)].; Состояние онкологической помощи населению России в 2009 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: ФГУ «МНИОИ им. П.А. Герцена Росмедтехнологий», 2010. 196 с. [State of oncological care in Russia in 2009. Eds.: V.I. Chissov, V.V. Starinskiy, G.V. Petrova. Moscow: FGU “MNIOI im. P.A. Gertzena Rosmedtekhnologiy”, 2010. 196 p. (In Russ.)].; Злокачественные новообразования в России в 2009 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: ФГУ «МНИОИ им. П.А. Герцена Минздравсоцразвития России», 2011. 260 с. [Malignant neoplasms in Russia in 2009 (morbidity and mortality). Eds.: V.I. Chissov, V.V. Starinskiy, G.V. Petrova. Moscow: FGU “MNIOI im. P.A. Gertzena Rosmedtekhnologiy”, 2011. 260 p. (In Russ.)].; Важенин А.В., Карнаух П.А. Эпидемиология рака предстательной железы в Челябинской области. Паллиативная медицина и реабилитация 2008;(2): 26–8. [Vazhenin A.V., Karnaukh P.A. Epidemiology of prostate cancer in Chelyabinsk Region. Palliativnaya meditsina i reabilitatsiya = Palliative Medicine and Rehabilitation 2008;(2): 26–8. (In Russ.)].; Katz A.J., Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol 2014;4:301. DOI:10.3389/fonc.2014.00301. PMID: 25389521.; Katz A.J., Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol 2014;4:240. DOI:10.3389/fonc.2014.00240. PMID: 25229051.; Sanfilippo N.J., Cooper B.T. Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. Am J Clin Exp Urol 2014;2(4):286–93. PMID: 25606574.; https://oncourology.abvpress.ru/oncur/article/view/649

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/649
https://doi.org/10.17650/1726-9776-2017-13-2-74-78

المؤلفون: Maria Cotesta, Rosaria Meucci, Francesca Santori, Francesca Servadei, Erica Giacobbi, Alessandra Vittoria Granai, Chiara Adriana Pistolese, Gianluca Vanni, Marco Pellicciaro, Gloria Marchese, Sandro Grelli, Marco Materazzo, Tommaso Perretta

المصدر: International Journal of Surgery Case Reports

مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.medical_treatment, Breast surgery, Sentinel lymph node, Case Report, Asymptomatic, Cancer treatments delay, Settore MED/07, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, skin and connective tissue diseases, Chemotherapy, business.industry, SARS-CoV-2, Micrometastasis, COVID-19, medicine.disease, 030220 oncology & carcinogenesis, Neoadjuvant hormone therapy, 030211 gastroenterology & hepatology, Surgery, medicine.symptom, business, Adjuvant, Hormone

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99ee3e3f3f46b79b06dd232577250b60
http://europepmc.org/articles/PMC7543888

المؤلفون: Akiko NAKAMURA, Daiki TAKATSUKA, Haruka ASAI, Hiroyuki OGURA, Norihiko SIYA, Yuko ASANO, 中村 明子, 小倉 廣之, 椎谷 紀彦, 浅井 はるか, 淺野 祐子, 髙塚 大輝

المصدر: 日本臨床外科学会雑誌 / Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 2019, 80(4):681

المؤلفون: Kipriyanov, Е. А., Kamaukh, P. A., Davydov, О. N., Vazhenin, A. V., Киприянов, Е. А., Карнаух, П. А., Давыдова, О. Н., Важенин, А. В.

مصطلحات موضوعية: PROSTATE CANCER, NEOADJUVANT HORMONE THERAPY, BRACHYTHERAPY 1-125, РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, НЕОАДЬЮВАНТНАЯ ГОРМОНОТЕРАПИЯ, БРАХИТЕРАПИЯ 1-125

وصف الملف: application/pdf

Relation: Уральский медицинский журнал. 2015. T. 132, № 9.; Брахитерапия 1-125 в лечения пациентов с предстательной железы / Е. А. Киприянов, П. А. Карнаух, О. Н. Давыдова, А. В. Важенин. – Текст: электронный // Уральский медицинский журнал. - 2015. – T. 132, № 9. – С. 145-148.; http://elib.usma.ru/handle/usma/14061

الاتاحة: http://elib.usma.ru/handle/usma/14061

المؤلفون: Bin Wu, Lijin Zhang, Jun Yuan, Zhenlei Zha, Yejun Feng, Hu Zhao

المصدر: Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2021)

مصطلحات موضوعية: Biochemical recurrence, medicine.medical_specialty, Cancer Research, medicine.medical_treatment, 030232 urology & nephrology, Urology, lcsh:RC254-282, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Medicine, business.industry, Prostatectomy, Odds ratio, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, prostate cancer, Confidence interval, radical prostatectomy, meta-analysis, Oncology, clinical research, 030220 oncology & carcinogenesis, Meta-analysis, Cohort, Systematic Review, business, Body mass index, neoadjuvant hormone therapy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8d0214956309105d52fc507199daf3
http://europepmc.org/articles/PMC7897693

مصطلحات موضوعية: первичная эндокринотерапия, bisphosphanates, relapse-free survival, пожилые пациентки, overall survival, безрецидивная выживаемость, elderly patients, primary endocrine therapy, бисфосфонаты, breast cancer, неоадъювантная гормонотерапия, общая выживаемость, рак молочной железы, neoadjuvant hormone therapy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::51d81963b0bd621feecaad7901bc3ea5

المؤلفون: Щепотін, І. Б., Зотов, О. С., Анікусько, М. Ф., Любота, І. І., Любота, Р. В.

المصدر: Clinical Endocrinology and Endocrine Surgery; No. 4(37) (2011); 3-10 ; Clinical Endocrinology and Endocrine Surgery; № 4(37) (2011); 3-10 ; 2519-2582 ; 1818-1384

مصطلحات موضوعية: breast cancer, neoadjuvant hormone therapy, antiestrogens, aromatase inhibitors, рак молочной железы, неоадъювантная гормонотерапия, антиэстрогены, ингибиторы ароматазы

وصف الملف: application/pdf

Relation: http://jcees.endocenter.kiev.ua/article/view/86405/82002; http://jcees.endocenter.kiev.ua/article/view/86405

الاتاحة: http://jcees.endocenter.kiev.ua/article/view/86405
https://doi.org/10.24026/1818-1384.4(37).2011.86405

المؤلفون: Lijin Zhang (627797), Hu Zhao (425380), Bin Wu (138543), Zhenlei Zha (5480096), Jun Yuan (356273), Yejun Feng (5712059)

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, prostate cancer, radical prostatectomy, neoadjuvant hormone therapy, meta-analysis, clinical research

Relation: https://figshare.com/articles/dataset/Table_1_The_Impact_of_Neoadjuvant_Hormone_Therapy_on_Surgical_and_Oncological_Outcomes_for_Patients_With_Prostate_Cancer_Before_Radical_Prostatectomy_A_Systematic_Review_and_Meta-Analysis_docx/13728556

الاتاحة: https://doi.org/10.3389/fonc.2020.615801.s002

المؤلفون: Lijin Zhang, Hu Zhao, Bin Wu, Zhenlei Zha, Jun Yuan, Yejun Feng

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, prostate cancer, radical prostatectomy, neoadjuvant hormone therapy, meta-analysis, clinical research

Relation: https://figshare.com/articles/figure/Image_1_The_Impact_of_Neoadjuvant_Hormone_Therapy_on_Surgical_and_Oncological_Outcomes_for_Patients_With_Prostate_Cancer_Before_Radical_Prostatectomy_A_Systematic_Review_and_Meta-Analysis_tif/13728550

الاتاحة: https://doi.org/10.3389/fonc.2020.615801.s001
https://figshare.com/articles/figure/Image_1_The_Impact_of_Neoadjuvant_Hormone_Therapy_on_Surgical_and_Oncological_Outcomes_for_Patients_With_Prostate_Cancer_Before_Radical_Prostatectomy_A_Systematic_Review_and_Meta-Analysis_tif/13728550

المؤلفون: Pellicciaro, Marco, Granai, Alessandra Vittoria, Marchese, Gloria, Materazzo, Marco, Cotesta, Maria, Santori, Francesca, Giacobbi, Erica, Servadei, Francesca, Grelli, Sandro, Perretta, Tommaso, Meucci, Rosaria, Pistolese, Chiara Adriana, Vanni, Gianluca

المساهمون: Pellicciaro, M, Granai, Av, Marchese, G, Materazzo, M, Cotesta, M, Santori, F, Giacobbi, E, Servadei, F, Grelli, S, Perretta, T, Meucci, R, Pistolese, Ca, Vanni, G

مصطلحات موضوعية: Breast cancer, COVID-19, Neoadjuvant hormone therapy, SARS-CoV-2, Cancer treatments delay, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA

Relation: info:eu-repo/semantics/altIdentifier/pmid/33052300; info:eu-repo/semantics/altIdentifier/wos/WOS:000608407300088; volume:76; firstpage:377; lastpage:380; numberofpages:4; journal:INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS; http://hdl.handle.net/2108/259072; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85092676955

الاتاحة: http://hdl.handle.net/2108/259072
https://doi.org/10.1016/j.ijscr.2020.10.020

المؤلفون: Albane Frati, G Allevi, Silvia Paola Corona, Lajos Pusztai, Manuela Milani, Sergio Aguggini, Roman Rouzier, Carla Strina, Daniele Generali

المساهمون: Generali, Daniele, Corona, Silvia Paola, Pusztai, Lajo, Rouzier, Roman, Allevi, Giovanni, Aguggini, Sergio, Milani, Manuela, Strina, Carla, Frati, Albane

المصدر: Journal of Cancer Research and Clinical Oncology. 144:601-606

مصطلحات موضوعية: 0301 basic medicine, Oncology, Hormone receptor positive breast cancer, BC, IGR/MDACC nomogram, Nomogram, Neoadjuvant therapy for breast cancer, Neoadjuvant chemotherapy, Neoadjuvant hormone therapy, HT, CT, HT plus CT combination, Pathological Complete Response, pCR, Cancer Research, medicine.medical_treatment, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Anthracyclines, Neoadjuvant therapy, Aged, 80 and over, education.field_of_study, Antibiotics, Antineoplastic, General Medicine, Middle Aged, Combined Modality Therapy, Neoadjuvant Therapy, Treatment Outcome, Chemotherapy, Adjuvant, Hormone receptor, 030220 oncology & carcinogenesis, Preoperative Period, Hormonal therapy, Female, medicine.drug, Adult, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Anthracycline, Population, Breast Neoplasms, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Humans, education, Aged, Retrospective Studies, business.industry, medicine.disease, Tamoxifen, 030104 developmental biology, Hormone therapy, business

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b7dbd35f3fda3267ba4d17126be6705
https://doi.org/10.1007/s00432-017-2574-4

المؤلفون: Laura Pizzuti, Cristiana Ercolani, Marcello Maugeri-Saccà, Irene Terrenato, Luciano Mariani, Marco Mazzotta, Francesca Sperati, Enrico Vizza, Antonino Grassadonia, Maddalena Barba, Camilla Marinelli, Silverio Tomao, Patrizia Vici, Nicola Tinari, Domenico Angelucci, Domenico Sergi, Anna Di Benedetto, Gennaro Ciliberto, Laura Iezzi, Clara Natoli, G. Paoletti

المصدر: Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 11 (2019)

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, DNA damage, medicine.medical_treatment, hormone-receptor-positive breast cancer, elderly patients, lcsh:RC254-282, prognostic biomarkers, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, Original Research, business.industry, DNA damage and repair, Endocrine therapy, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, Hormone receptor, 030220 oncology & carcinogenesis, Hormone therapy, business, neoadjuvant hormone therapy

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39bda1feccc2297d81c999d74a930892
http://europepmc.org/articles/PMC6700857